Literature DB >> 10823140

Value of A103 (melan-A) immunostaining in the differential diagnosis of ovarian sex cord stromal tumours.

C J Stewart1, C L Nandini, J A Richmond.   

Abstract

AIMS: To assess A103 (melan-A) immunoreactivity in a range of ovarian sex cord stromal tumours and to evaluate it for the differential diagnosis of other neoplasms.
METHODS: Paraffin embedded tissue sections from 45 sex cord stromal tumours and 44 potential histological mimics were examined immunohistochemically using the antibody A103. The sex cord stromal group included 21 adult granulosa cell tumours (AGCT), two juvenile granulosa cell tumours (JGCT), eight tumours showing Sertoli cell or Sertoli-Leydig cell differentiation, two unclassified tumours, two gonadoblastomas, one sex cord tumour with annular tubules, two steroid cell tumours, five thecomas/fibrothecomas, and two sclerosing stromal tumours. The histological mimics include 14 primary ovarian carcinomas, 13 metastatic carcinomas, four carcinoid tumours, four lymphomas, three endometrioid stromal sarcomas, two ovarian tumours of probable Wolffian origin, and one case each of small cell carcinoma, desmoplastic small round cell tumour, melanoma, and primitive neuroectodermal tumour.
RESULTS: A103 immunoreactivity was identified in 25 sex cord stromal tumours including 10 AGCT, two JGCT, six Sertoli/Sertoli-Leydig cell tumours, two steroid cell tumours, three thecomas/fibrothecomas, and two sclerosing stromal tumours. Of the potential histological mimics, staining was present only in the two ovarian tumours of probable Wolffian origin and the melanoma. Immunoreactive stromal cells were noted in a minority of cases. Normal hilus cells and rete ovarii epithelium also expressed A103.
CONCLUSIONS: A103 is a moderately sensitive and specific marker of sex cord stromal differentiation within the range of tumours examined in this study and as such is a valuable adjunct to other immunocytochemical markers in the assessment of diagnostically problematic ovarian tumours. The staining of normal and neoplastic Wolffian elements merits further investigation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10823140      PMCID: PMC1731158          DOI: 10.1136/jcp.53.3.206

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  30 in total

1.  The diagnostic utility of inhibin staining in ovarian neoplasms.

Authors:  T J Pelkey; H F Frierson; S E Mills; M H Stoler
Journal:  Int J Gynecol Pathol       Date:  1998-04       Impact factor: 2.762

2.  Immunohistochemical staining of ovarian granulosa cell tumors with monoclonal antibody against inhibin.

Authors:  W G McCluggage; P Maxwell; J M Sloan
Journal:  Hum Pathol       Date:  1997-09       Impact factor: 3.466

3.  A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues.

Authors:  A A Jungbluth; K J Busam; W L Gerald; E Stockert; K A Coplan; K Iversen; D P MacGregor; L J Old; Y T Chen
Journal:  Am J Surg Pathol       Date:  1998-05       Impact factor: 6.394

4.  Uterine tumors resembling ovarian sex-cord tumors have an immunophenotype consistent with true sex-cord differentiation.

Authors:  S Krishnamurthy; A A Jungbluth; K J Busam; J Rosai
Journal:  Am J Surg Pathol       Date:  1998-09       Impact factor: 6.394

5.  Value of inhibin in the identification of granulosa cell tumors of the ovary.

Authors:  R H Hildebrandt; R V Rouse; T A Longacre
Journal:  Hum Pathol       Date:  1997-12       Impact factor: 3.466

6.  Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants.

Authors:  K Blessing; D S Sanders; J J Grant
Journal:  Histopathology       Date:  1998-02       Impact factor: 5.087

7.  Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections.

Authors:  O Kaufmann; S Koch; J Burghardt; H Audring; M Dietel
Journal:  Mod Pathol       Date:  1998-08       Impact factor: 7.842

8.  CD99, keratin, and vimentin staining of sex cord-stromal tumors, normal ovary, and testis.

Authors:  M D Gordon; C Corless; A A Renshaw; J Beckstead
Journal:  Mod Pathol       Date:  1998-08       Impact factor: 7.842

9.  Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.

Authors:  K J Busam; Y T Chen; L J Old; E Stockert; K Iversen; K A Coplan; J Rosai; R L Barnhill; A A Jungbluth
Journal:  Am J Surg Pathol       Date:  1998-08       Impact factor: 6.394

10.  Inhibin expression in ovarian tumors and tumor-like lesions: an immunohistochemical study.

Authors:  F Kommoss; E Oliva; A K Bhan; R H Young; R E Scully
Journal:  Mod Pathol       Date:  1998-07       Impact factor: 7.842

View more
  5 in total

1.  Sclerosing stromal tumour in young women: clinicopathologic and immunohistochemical spectrum.

Authors:  Ecmel Isik Kaygusuz; Suna Cesur; Handan Cetiner; Hulya Yavuz; Nermin Koc
Journal:  J Clin Diagn Res       Date:  2013-08-10

2.  Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas.

Authors:  Ozgür Mete; Yersu Kapran; Mine G Güllüoğlu; Işin Kiliçaslan; Yeşim Erbil; Yasemin Giles Senyürek; Ferhunde Dizdaroğlu
Journal:  Virchows Arch       Date:  2010-05       Impact factor: 4.064

3.  Uterine tumour resembling ovarian sex cord tumour is an immunohistochemically polyphenotypic neoplasm which exhibits coexpression of epithelial, myoid and sex cord markers.

Authors:  D P Hurrell; W G McCluggage
Journal:  J Clin Pathol       Date:  2006-12-20       Impact factor: 3.411

4.  [Immunohistochemical sex cord markers. Description and use in the differential diagnosis of ovarian tumors].

Authors:  F Kommoss; D Schmidt
Journal:  Pathologe       Date:  2007-05       Impact factor: 1.011

Review 5.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.